Evidence Development
Expect more from your evidence
We provide expert-driven real-world evidence tailored to specialty patient populations to uncover more valuable insights, maximize commercial positioning and optimize regulatory approval for the long-term value of your therapy.
Generate Fit-for-Purpose Evidence to Support the Product Life Cycle
UBC’s expert, multi-disciplinary, real-world evidence (RWE) team supports biopharma in developing valuable evidence on the safety, effectiveness, and value of treatments. We do this through expert strategic consulting, research design, and operational delivery of modernized studies that leverage best-in-class data acquisition technologies.
An Experienced Real-World Evidence Partner
Decades of thought partnership and operational delivery of RWE programs.
UBC is an industry-recognized leader with over 20 years of world-class observational research and RWE experience. We develop end-to-end integrated evidence-generation strategies, identify fit-for-purpose data sources, operationalize full-service study solutions, and produce regulatory-grade, publishable analysis. Our team is unmatched, with decades of relevant epidemiology, medical, scientific, and data science expertise. We are purpose-built for RWE and post-marketing research.
The UBC Difference in Evidence Development
A complete offering of RWE solutions to meet your needs at any stage of the product lifecycle.
A partner you can trust to build an RWE program with intelligent foresight and patient-centric results.
Modernized Study Design & Execution
- Decentralized and Hybrid Studies
- Patient & Site Recruitment
- Real-World Data Acquisition & Technology
Late-Stage Research
- Registration & Marketing Authorization
- Post Marketing Requirements (FDA PMR / EMA PASS)
- Line Extension
- Label Expansion
- Publication Strategy
- Expanded Access Prior to Approval
- Market Access to Support HTA Decision Making
Learn More About UBC's Evidence Development Strategic Approach
Interested in learning more about how UBC’s evidence development strategic approach can help you unite evidence and access to inform complex decisions?
